BL M11D1
Alternative Names: BL-M11D1; BL-M11D1-ADCLatest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Sichuan Baili Pharmaceutical
- Class Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; DNA topoisomerase I inhibitors; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 07 Dec 2024 Efficacy and adverse event data from a phase I trial in Acute myeloid Leukemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem)
- 14 Oct 2024 US FDA approves IND application for BL M11D1 in Acute myeloid leukaemia
- 14 Oct 2024 SystImmune plans a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV)